MBIO - FDA accepts Mustang Bio's MB-106 application in cancer

Mustang Bio (MBIO) announces that the FDA has accepted its Investigational New Drug ((IND)) application to initiate a Phase 1/2 study to assess the safety, tolerability and efficacy of MB-106, a CD20-targeted CAR T therapy for relapsed or refractory CD20+ B-cell non-Hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia ((CLL)). The CAR T therapy was exclusively licensed to Mustang in 2017, and Fred Hutch and Mustang collaborated to develop the cell processing that will be used in the Mustang IND Phase 1/2 clinical trial.MBIO shares up 2.6% premarket trading at $3.13.

For further details see:

FDA accepts Mustang Bio's MB-106 application in cancer